Skip to main content
Top
Published in: Inflammation 1/2012

01-02-2012

Interaction of Serine Proteases from Polymorphonuclear Leucocytes with the Cell Surface and Heparin

Authors: Jana Fleddermann, Annelie Pichert, Jürgen Arnhold

Published in: Inflammation | Issue 1/2012

Login to get access

Abstract

Polymorphonuclear leucocytes (PMNs) accumulate at inflammatory sites and contribute to host defence, regulation of the inflammatory process, and also to tissue injury. Upon activation, these cells release the serine proteases elastase, cathepsin G, and proteinase 3 that are involved in multiple processes such as microbicidal activity, penetration of PMNs through endothelium and adjacent connective tissue to inflammatory sites, and processing of various cytokines. Here, we compared the three serine proteases for their release from PMNs and their ability to interact with resting PMNs and the highly sulphated glycosaminoglycan heparin. Unlike elastase, proteinase 3 and cathepsin G were released from resting PMNs as evidenced by flow cytometry, confocal fluorescence microscopy, and activity measurements. While proteinase 3 binds heavily to surface targets on vital PMNs, cathepsin G and elastase interact preferentially with sulphated glycosaminoglycans. These data revealed a differentiated picture about the individual functions of the PMN serine proteases during inflammatory response.
Literature
1.
go back to reference Muller, W.A. 2002. Leukocyte-endothelial cell interactions in the inflammatory response. Laboratory Investigation 82: 521–533.PubMedCrossRef Muller, W.A. 2002. Leukocyte-endothelial cell interactions in the inflammatory response. Laboratory Investigation 82: 521–533.PubMedCrossRef
2.
go back to reference Taylor, K.R., and R.L. Gallo. 2006. Glycosaminoglycans and their proteoglycans: host-associated molecular pattern for initiation and modulation of inflammation. The FASEB Journal 20: 9–22.PubMedCrossRef Taylor, K.R., and R.L. Gallo. 2006. Glycosaminoglycans and their proteoglycans: host-associated molecular pattern for initiation and modulation of inflammation. The FASEB Journal 20: 9–22.PubMedCrossRef
3.
go back to reference Fadok, V.A., D.L. Bratton, A. Konowal, P.W. Freed, J.Y. Westcott, and P.M. Henson. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-ß, PGE2, and PAF. The Journal of Clinical Investigation 101: 890–898.PubMedCrossRef Fadok, V.A., D.L. Bratton, A. Konowal, P.W. Freed, J.Y. Westcott, and P.M. Henson. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-ß, PGE2, and PAF. The Journal of Clinical Investigation 101: 890–898.PubMedCrossRef
4.
5.
go back to reference Walker, A., C. Ward, E.L. Taylor, I. Dransfield, S.P. Hart, C. Haslett, and A.G. Rossi. 2005. Regulation of neutrophil apoptosis and removal of apoptotic cells. Current Drug Targets. Inflammation and Allergy 4: 447–454.PubMedCrossRef Walker, A., C. Ward, E.L. Taylor, I. Dransfield, S.P. Hart, C. Haslett, and A.G. Rossi. 2005. Regulation of neutrophil apoptosis and removal of apoptotic cells. Current Drug Targets. Inflammation and Allergy 4: 447–454.PubMedCrossRef
6.
go back to reference Krysko, D.V., K. D’Herde, and P. Vandenabeele. 2006. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 11: 1709–1726.PubMedCrossRef Krysko, D.V., K. D’Herde, and P. Vandenabeele. 2006. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 11: 1709–1726.PubMedCrossRef
7.
go back to reference Erwig, L.-P., and P.M. Henson. 2007. Immunological consequences of apoptotic cell phagocytosis. The American Journal of Pathology 171: 2–8.PubMedCrossRef Erwig, L.-P., and P.M. Henson. 2007. Immunological consequences of apoptotic cell phagocytosis. The American Journal of Pathology 171: 2–8.PubMedCrossRef
8.
go back to reference Vandivier, R.W., P.M. Henson, and I.S. Douglas. 2006. Burying the dead. The impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 129: 1673–1682.PubMedCrossRef Vandivier, R.W., P.M. Henson, and I.S. Douglas. 2006. Burying the dead. The impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 129: 1673–1682.PubMedCrossRef
9.
go back to reference Meyer-Hoffert, U. 2009. Neutrophil-derived serine proteases modulate innate immune response. Frontiers in Bioscience 14: 409–3418. Meyer-Hoffert, U. 2009. Neutrophil-derived serine proteases modulate innate immune response. Frontiers in Bioscience 14: 409–3418.
10.
go back to reference Kessenbrock, K., T. Dau, and D.E. Jenne. 2011. Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. Journal of Molecular Medicine 89: 23–28.PubMedCrossRef Kessenbrock, K., T. Dau, and D.E. Jenne. 2011. Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. Journal of Molecular Medicine 89: 23–28.PubMedCrossRef
11.
go back to reference Pham, C.T.N. 2006. Neutrophil serine proteases: specific regulators of inflammation. Nature Reviews. Immunology 6: 541–550.PubMedCrossRef Pham, C.T.N. 2006. Neutrophil serine proteases: specific regulators of inflammation. Nature Reviews. Immunology 6: 541–550.PubMedCrossRef
12.
go back to reference Kantari, C., M. Pederzoli-Ribeil, O. Amir-Moazami, V. Gausson-Dorey, I. Cruz Moura, M.-C. Lecomte, M. Benhoume, and V. Witko-Sarsat. 2007. Proteinase 3, the Wegener autoantigen, is externalized during neutrophil apoptosis: evidence for a functional association with phospholipid scramblase 1 and interference with macrophage phagocytosis. Blood 110: 4086–4095.PubMedCrossRef Kantari, C., M. Pederzoli-Ribeil, O. Amir-Moazami, V. Gausson-Dorey, I. Cruz Moura, M.-C. Lecomte, M. Benhoume, and V. Witko-Sarsat. 2007. Proteinase 3, the Wegener autoantigen, is externalized during neutrophil apoptosis: evidence for a functional association with phospholipid scramblase 1 and interference with macrophage phagocytosis. Blood 110: 4086–4095.PubMedCrossRef
13.
go back to reference Frommherz, K.J., B. Faller, and J.G. Bieth. 1991. Heparin strongly decreases the rate of inhibition of neutrophil elastase by α1-proteinase inhibitor. The Journal of Biological Chemistry 266: 15356–15362.PubMed Frommherz, K.J., B. Faller, and J.G. Bieth. 1991. Heparin strongly decreases the rate of inhibition of neutrophil elastase by α1-proteinase inhibitor. The Journal of Biological Chemistry 266: 15356–15362.PubMed
14.
go back to reference Ermolieff, J., C. Boudier, A. Laine, B. Meyer, and J.G. Bieth. 1994. Heparin protects cathepsin G against inhibition by protein proteinase inhibitors. The Journal of Biological Chemistry 269: 29502–29508.PubMed Ermolieff, J., C. Boudier, A. Laine, B. Meyer, and J.G. Bieth. 1994. Heparin protects cathepsin G against inhibition by protein proteinase inhibitors. The Journal of Biological Chemistry 269: 29502–29508.PubMed
15.
go back to reference Korkmaz, B., J. Jaillet, M.-L. Jourdan, A. Gauthier, F. Gauthier, and S. Attucci. 2009. Catalytic activity and inhibition of Wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils. The Journal of Biological Chemistry 284: 19896–19902.PubMedCrossRef Korkmaz, B., J. Jaillet, M.-L. Jourdan, A. Gauthier, F. Gauthier, and S. Attucci. 2009. Catalytic activity and inhibition of Wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils. The Journal of Biological Chemistry 284: 19896–19902.PubMedCrossRef
16.
go back to reference Hu, N., J. Westra, and C.G.M. Kallenberg. 2009. Membrane-bound proteinase 3 and its receptors: relevance for the pathogenesis of Wegener’s granulomatosis. Autoimmunity Reviews 8: 510–514.PubMedCrossRef Hu, N., J. Westra, and C.G.M. Kallenberg. 2009. Membrane-bound proteinase 3 and its receptors: relevance for the pathogenesis of Wegener’s granulomatosis. Autoimmunity Reviews 8: 510–514.PubMedCrossRef
17.
go back to reference Coakley, R.J., C. Taggart, S. O’Neill, and N.G. McElvaney. 2001. Alpha1-antitrypsin deficiency: biological answers to clinical questions. The American Journal of the Medical Sciences 321: 33–41.PubMedCrossRef Coakley, R.J., C. Taggart, S. O’Neill, and N.G. McElvaney. 2001. Alpha1-antitrypsin deficiency: biological answers to clinical questions. The American Journal of the Medical Sciences 321: 33–41.PubMedCrossRef
18.
go back to reference Erlanger, B.F., N. Kokowsky, and W. Cohen. 1961. The preparation and properties of two new chromogenic substrates of trypsin. Archives of Biochemistry and Biophysics 95: 271–278.PubMedCrossRef Erlanger, B.F., N. Kokowsky, and W. Cohen. 1961. The preparation and properties of two new chromogenic substrates of trypsin. Archives of Biochemistry and Biophysics 95: 271–278.PubMedCrossRef
19.
go back to reference Lominadze, G., D.W. Powell, G.C. Luerman, A.J. Link, R.A. Ward, and K.R. McLeish. 2005. Proteomic analysis of human neutrophil granules. Molecular & Cellular Proteomics 4: 1503–1521.CrossRef Lominadze, G., D.W. Powell, G.C. Luerman, A.J. Link, R.A. Ward, and K.R. McLeish. 2005. Proteomic analysis of human neutrophil granules. Molecular & Cellular Proteomics 4: 1503–1521.CrossRef
20.
go back to reference Csernok, E., J. Lüdemann, W.L. Gross, and D.F. Bainton. 1990. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener’s granulomatosis. The American Journal of Pathology 137: 1113–1120.PubMed Csernok, E., J. Lüdemann, W.L. Gross, and D.F. Bainton. 1990. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener’s granulomatosis. The American Journal of Pathology 137: 1113–1120.PubMed
21.
go back to reference Halbwachs-Mecarelli, L., G. Bessou, P. Lesavre, S. Lopez, and V. Witko-Sarsat. 1995. Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Letters 374: 29–33.PubMedCrossRef Halbwachs-Mecarelli, L., G. Bessou, P. Lesavre, S. Lopez, and V. Witko-Sarsat. 1995. Bimodal distribution of proteinase 3 (PR3) surface expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Letters 374: 29–33.PubMedCrossRef
22.
go back to reference Witko-Sarsat, V., L. Halbwachs-Mecarelli, A. Schuster, P. Nusbaum, I. Ueki, S. Canteloup, G. Lenoir, B. Descamps-Latscha, and J.A. Nadel. 1999. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. American Journal of Respiratory Cell and Molecular Biology 20: 729–736.PubMed Witko-Sarsat, V., L. Halbwachs-Mecarelli, A. Schuster, P. Nusbaum, I. Ueki, S. Canteloup, G. Lenoir, B. Descamps-Latscha, and J.A. Nadel. 1999. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. American Journal of Respiratory Cell and Molecular Biology 20: 729–736.PubMed
23.
go back to reference Faurschou, M., and N. Borregard. 2003. Neutrophil granules and secretory vesicles in inflammation. Microbes and Infection 5: 1317–1327.PubMedCrossRef Faurschou, M., and N. Borregard. 2003. Neutrophil granules and secretory vesicles in inflammation. Microbes and Infection 5: 1317–1327.PubMedCrossRef
24.
go back to reference Choi, M., C. Eulenberg, S. Rolle, J.P. von Kries, F.C. Luft, and R. Kettritz. 2010. The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction. Clinical and Experimental Immunology 161: 389–396.PubMed Choi, M., C. Eulenberg, S. Rolle, J.P. von Kries, F.C. Luft, and R. Kettritz. 2010. The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction. Clinical and Experimental Immunology 161: 389–396.PubMed
25.
go back to reference Goldmann, W.H., J.L. Niles, and M.A. Arnaout. 1999. Interaction of purified proteinase 3 (PR3) with reconstituted lipid bilayers. European Journal of Biochemistry 261: 155–162.PubMedCrossRef Goldmann, W.H., J.L. Niles, and M.A. Arnaout. 1999. Interaction of purified proteinase 3 (PR3) with reconstituted lipid bilayers. European Journal of Biochemistry 261: 155–162.PubMedCrossRef
26.
go back to reference Campbell, E.J., and C.A. Owen. 2007. The sulfate groups of chondroitin sulfate- and heparan sulfate-containing proteoglycans in neutrophil plasma membranes are novel binding sites for human leukocyte elastase and cathepsin G. The Journal of Biological Chemistry 282: 14645–14654.PubMedCrossRef Campbell, E.J., and C.A. Owen. 2007. The sulfate groups of chondroitin sulfate- and heparan sulfate-containing proteoglycans in neutrophil plasma membranes are novel binding sites for human leukocyte elastase and cathepsin G. The Journal of Biological Chemistry 282: 14645–14654.PubMedCrossRef
27.
go back to reference Korkmaz, B., A. Kuhl, B. Bayat, S. Santoso, and D.E. Jenne. 2008. A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. The Journal of Biological Chemistry 283: 35976–35982.PubMedCrossRef Korkmaz, B., A. Kuhl, B. Bayat, S. Santoso, and D.E. Jenne. 2008. A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. The Journal of Biological Chemistry 283: 35976–35982.PubMedCrossRef
28.
go back to reference Zani, M.L., K. Baranger, N. Guyot, S. Dallet-Choisy, and T. Moreau. 2009. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Protein Science 18: 579–594.PubMed Zani, M.L., K. Baranger, N. Guyot, S. Dallet-Choisy, and T. Moreau. 2009. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Protein Science 18: 579–594.PubMed
29.
go back to reference Gupta, V.K., and L.R. Gowda. 2008. Alpha-1-proteinase inhibitor is a heparin binding serpin: molecular interactions with the Lys rich cluster of helix-F domain. Biochimie 90: 749–761.PubMedCrossRef Gupta, V.K., and L.R. Gowda. 2008. Alpha-1-proteinase inhibitor is a heparin binding serpin: molecular interactions with the Lys rich cluster of helix-F domain. Biochimie 90: 749–761.PubMedCrossRef
30.
go back to reference Serhan, C.N., N. Chiang, and T.E. van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews. Immunology 8: 349–361.PubMedCrossRef Serhan, C.N., N. Chiang, and T.E. van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews. Immunology 8: 349–361.PubMedCrossRef
Metadata
Title
Interaction of Serine Proteases from Polymorphonuclear Leucocytes with the Cell Surface and Heparin
Authors
Jana Fleddermann
Annelie Pichert
Jürgen Arnhold
Publication date
01-02-2012
Publisher
Springer US
Published in
Inflammation / Issue 1/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9292-x

Other articles of this Issue 1/2012

Inflammation 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine